You need a license to cut-and-paste this copyrighted news content.
Use this link to purchase your paid subscription ($200/year for individuals and $1,000/year for companies of every size):
Already a paid subscriber? Sign in to Endpoints News to remove this message.

Before I owned a record label, I used to write a syndicated album review column. One of the series we ran was on the ‘golden streaks’ – the 3 album runs that have tended to define the peak of the careers of most of the ‘classic artists’, from Stevie Wonder to Sinatra to Led Zeppelin. It is possible that we have just witnessed our own industry’s punk period – older artists still selling well, bringing in the crowds, but the power now being in the hands of smaller, self-made artists, who may never feel compelled to ‘sell out’.

The Pharmaceutical Innovation Index measures, scores and celebrates a company’s ability to deliver innovation to patients, by objectively evaluating performance based on a rolling five year period (2013-2018), and operates on the simple premise: if you gave the same molecule to two different companies in early phase, which would make the best of it? This year provides perhaps the strongest indication yet of how unevenly distributed that competency (launching meaningful medicines) is…

Gilead has risen consistently, by one place per year since 2016, to the top of the table, with an outstanding antiviral performance – in 2018, Gilead derived 60% of its revenues from new drugs, more than twice any other company, and 6 times more than the average across the top 30. It should also be noted that Gilead are the only company consistently delivering new drugs that hit what we’d traditionally call ‘blockbuster’ status within 2-3 years of launch. Read more here.